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Objectives: To determine whether increased levels of B cell activating factor (BAFF) in patients with 
Systemic Lupus Erythematosus (SLE) are due to disease activity or genetic variations in the promoter 
region of the BAFF gene and BAFF gene expression. 
Methods:  The case control study included 101 SLE patients and 111 healthy controls. Five single 
nucleotide polymorphisms (SNPs) in the BAFF promoter region were investigated by melting point 
analysis; c.-2841 (T>C), c.-2704 (T>C), c.-2701 (A>T), c.-871 (C>T) and c.-514 (A>G). BAFF mRNA 
levels were determined by real time PCR (BAFF-RQ) and serum BAFF (s-BAFF) levels were measured 
by ELISA. Independent predictors that might be correlated with increased s-BAFF in SLE patients were 
analysed by multivariate regression methods. 
Results: Although s-BAFF levels were increased in SLE patients (1.73 vs. 0.98 ng/μl, p<0.001), no 
specific BAFF genotype was found to associate with SLE. The different genotypes defined by the 
investigated SNPs were identified both in SLE patients and healthy controls with similar frequencies. 
No association was found between BAFF genotype and BAFF-RQ. S-BAFF was independently of 
other factors, correlated with CRP (β 0.40, p<0.001), physicians visual analogue score (Rs 0.21 
p=0.046) and inversely with haemoglobin (β -0.32, p<0.001) and IgA (β -0.33, p=0.001).   
Conclusions: Increased s-BAFF levels in SLE patients are associated with the acute phase responses 
CRP and haemoglobin, but probably not dependent on BAFF genotype or expression. This indicates 
that s-BAFF production occurs at sites of inflammation. 
 







B-cell activating factor belonging to the tumor necrosis factor (TNF) superfamily (TNFSF13, 
BAFF or BLyS) is an important stimulatory factor for B-cell development and homeostasis (1). 
BAFF synthesis occurs in a range of immune cells (2) and can be enhanced through stimulation by 
inflammatory cytokines like IL-2 and INF-γ (3;4). Depending of the different receptor on mature B 
cells (BAFF-R, TACI and BCMA), the binding of BAFF with receptors induces Ig class switching, 
cell proliferation and increased survival of B cells (5). These aspects of B cell functioning are all 
relevant in the pathogenesis of human SLE, but most of our knowledge on BAFF originates from 
experimental models. Transgenic mice over expressing BAFF develop B-cell hyperplasia and 
hypergammaglobulinemia, a striking increase in circulating autoantibodies and immune complex 
mediated disease with features of SLE and primary Sjögren’s syndrome (pSS) (6-8). In lupus prone 
mice, s-BAFF levels are increased at disease onset and blocking BAFF-dependent signals with 
soluble receptor prolongs their survival (9). In SLE patients, s-BAFF levels are frequently elevated 
and associated with disease activity including anti-dsDNA antibodies (Ab) levels (10-13). While 
these findings suggests that BAFF may be involved in the selective loss of B-cell tolerance in human 
SLE, the mechanisms responsible for increased s-BAFF levels in SLE remain unclear (5).  
Genetic predisposition is an important factor in the development and expression of systemic 
autoimmune disease in general and characteristic B cell hyperactivity in SLE patients may be related 
to specific polymorphisms in B cell signalling genes (14-16). The only report on BAFF genetics is in 
Japanese SLE patients, and no associations between disease susceptibility and single nucleotide 
polymorphisms (SNPs) in the 5 'regulatory region of the BAFF gene (13q32-34) were shown (17). 
BAFF genotype data of non Asian SLE patients are currently lacking. However, in a study of 
Caucasian patients with primary Sjögren's syndrome (pSS) an association between anti-Ro/La 
positive patients and a specific BAFF haplotype (CTAT) was shown (18). Furthermore, the BAFF c.-
871 T allele in the regulatory region of the BAFF gene was associated with increased s-BAFF in pSS 
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patients (18;19). Accordingly, this SNP may be involved in increased BAFF expression. In a cross 
sectional study on Chinese SLE patients, BAFF gene expression in peripheral blood mononuclear 
cells (PBMCs) was shown to be correlated with disease activity and anti-dsDNA Ab levels (20), 
whereas in a longitudinal North American study, BAFF mRNA was not associated with s-BAFF 
levels in 60% of patients (12). The discrepancy between s-BAFF levels and BAFF mRNA 
expression in PBMCs could indicate that in vivo BAFF production also occurs in other cells/tissue. 
As there are no data that combine BAFF genotype, BAFF gene expression and s-BAFF with 
clinical data in SLE patients, we investigated if any associations exist in vivo, between regulatory 
genetic polymorphisms, BAFF gene expression and/or s-BAFF levels with regard to disease 
susceptibility and disease phenotype.  
 
Materials and methods 
1. Study participants 
Hundred and one SLE patients (>15 years) were investigated. The patients were mainly (99%) of 
Caucasian descent; 87% were female, the median age was 47 years and the median disease duration 
was 10 years. All patients fulfilled the revised and/or updated American College of Rheumatology 
(ACR) criteria for the classification of SLE (21;22). Patients attended an extended clinic visit, where 
clinical data and biological material were taken simultaneously. Healthy volunteers (all Caucasian, 
71% females and median age 48 years) were used as controls for serological investigations, gene 
expression studies and genotype analyses. The study protocol was approved by the local ethical 
committee, the national privacy agency and the Ministry of Health (ref. no 12420) and all 
participants gave written informed consent for the anonymous use of their data in compliance with 




2. Clinical categorization of patients 
Lupus Nephritis (LN) designates patients with proteinuria (>0.5 g/24 hours) and/or the presence of 
>5 red blood cells and/or heme-granular or red blood cells casts (23).  Secondary Sjögren’s 
syndrome was defined as chronic sicca complaints with evidence of reduced tear and/or saliva 
production. Skin disease was defined as the presence of oral ulcers, malar or discoid rash as defined 
in SLEDAI. The disease activity and organ damage were scored according to SLE Disease Activity 
Index (SLEDAI) and Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI) 
(23;24). Patient and physician estimates for global disease activity were score on a visual analog 
scale (VAS; range 0-100mm) (25) 
 
3. Serology  
Serum BAFF levels were measured in duplex using a Quantikine Human BAFF/BLyS/TNFSF13B 
Immunoassay (R&D Systems, Minneapolis, USA) and results were averaged. Anti-nuclear 
antibodies (ANA) positive sera were routinely tested by enzyme immunoassays EIiA (VarELISA 
Phadia, Freiburg, Germany) for the presence of IgG subclass antibodies against double stranded 
DNA (anti-dsDNA),  Ro (anti-SSA), La (anti-SSB), Smith (anti-Sm) anti-U1 small nuclear 
ribonucleoparticle (anti-U1-snRNP) and  cardiolipin (aCL-G and aCL-M; normal levels <16IU/mL).  
 
4. SNP analysis  
4.1 Haplotype 
We identified five common haplotypes in the 5' regulatory region within 5kb of the first exon of the 
BAFF gene (chromosome 13, 107715-107725K) with the use of Caucasian (CEU) family data from 
the HapMap project (www.hapmap.org) or SNP database (www.ncbi.nlm.nih.gov/snp). These 
haplotypes were tagged by SNP rs9514827 (c.-2841 T>C), rs3759467 (c.-2704 T>C), rs1041569 (c.-
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2701 A>T), rs9514828 (c.-871 C>T) and rs3759465 (c.-514 A>G) (Figure1). Genotype and 
haplotype analyses were performed with SNPStats software (26). 
 
4.2 Primers and probes 
Genomic DNA was extracted from PBMCs and purified according to the instructions provided 
(Puregene Genomic DNA purification Kit, Gentra systems, Minneapolis, USA). Primers were 
designed for regions flanking each SNP. For specific detection of SNPs we used fluorescence 
resonance energy transfer (FRET) probes labelled with fluorescein and LC-Red 640 or LC-Red 705 
(TIB Molbiol, Berlin, Germany). Primers and probes were designed using the LightCycler Probe 
Design Software (Roche Diagnostics, Mannheim, Germany) and the sequences are specified in the 
supplemental Table.   
 
4.3 PCR and melting curve analysis 
All PCR assays for SNP analysis were performed on a LightCycler1.2 (Roche Diagnostics, 
Mannheim, Germany) under the following conditions: 2μl DNA Master HybProbe solution (Roche 
Diagnostics, Mannheim, Germany), 3mM MgCl2, 1μM of each primer, 0.15µM of each probe and 2μl 
templates in a final volume of 20μl. The SNPs c.-2841, c.-2704 and c.-2701 were analysed in a single 
tube using the following temperature program: Amplifications with initial denaturation at 94°C for 
30sec followed by 35 cycles at 55ºC for 15sec and 72 ºC for 19sec. Directly after amplification, 
melting curve analysis was performed by continuous measurement of the emitted light at temperatures 
increasing from 35° to 80°C. The two other SNPs (c.-871 and c.-514) were analysed in separate tubes, 
using the same temperature program except that elongation time at 72°C was 15sec. The SNP assay 
findings were confirmed by sequencing of different genotypes using BigDye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, CA, USA).  
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5. BAFF gene expression.   
5.1 Design of primers and probes 
Primers and probes were designed using the BAFF encoding gene TNFSF13B (NC_000013.10) and 
B2M gene encoding β2-microglobulin (β2M) (NC_000015.9) as templates. Primers were designed 
using Enhanced Avian HS RT-PCR software (Sigma-Aldrich, Saint Quentin Fallavier, France) and 
probes were selected using Universal ProbeLibrary Human Gene Assay (Roche Diagnostics, 
Mannheim, Germany) (supplemental Table). 
 
5.2 RNA extraction and cDNA synthesis  
Total RNA from frozen PBMCs was extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany), 
following manufacturer’s instructions. RNA was DNaseI treated (RNA-free), and stored at -80ºC. 
Total RNA (2μg) was used to synthesize cDNA in a total volume of 20μL using SuperScript VILO 
cDNA Synthesis Kit (Invitrogen, CA, USA) with regard of investigation full-length BAFF mRNA, 
according to the protocol. The quality of cDNA was then confirmed by PCR using cDNA (0.5μl), 
adenine phosphoribosyltransferase gene (APRT) primers (5pM) and Jumpstart ready mix Red Taq 
DNA polymerase (Sigma-Aldrich, Saint Quentin Fallavier, France). Thermal conditions were 
denaturation at 94ºC for 2min., 35 cycles at 94ºC for 10sec. 65ºC for 10sec., and 72 ºC for 15sec. and 
a final extension at 72ºC for 5min. Agarose gel electrophoresis were run to ensure quality of cDNA, 
which was stored at  −20°C. 
 
5.3 RT-PCR 
Real-time PCR analysis was performed to determine the levels of BAFF mRNA in PBMCs using an 
ABI PRISM 7900HT, (version 2.3, Applied Biosystems, CA, USA). PCR reaction mixture contained 
4μl cDNA, 10μl TaqMan MasterMix (TaqMan® Fast Universal PCR Master Mix (2x), No 
AmpErase® UNG, (Applied Biosystems), 5μM of each primer and probe in a final volume of 20μl. 
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Each analysis was performed with initial incubation at 95ºC for 20sec., followed by 40 cycles at 
95ºC for 1sec. and 60ºC for 20sec. PCR reactions were done in triplicates. A range of primer 
concentrations was tested to ensure optimal amplification efficiency. Relative concentrations of 
cDNA present during the exponential phase of the reaction were determined by plotting fluorescence 
against cycle number on a logarithmic scale. A threshold for detection of fluorescence above 
background was determined. The BAFF transcript quantification was standardized using β2M as 
internal control. BAFF-RQ are calculated as the ratios of BAFF mRNA to β2M mRNA using the 
following formula: 2 exp(Ctβ2M – CtBAFF). Cut-off levels were determined by the geometric mean 
+2 S.D. for healthy controls (n=31). The amplification was verified by melting curve analysis and 
crossing point. No amplification of non-specific products was observed. 
 
6. Statistics  
As most data had a skewed distribution, numbers reported are median values unless indicated 
otherwise and nonparametric test methods were used in statistical analyses. Continuous data were 
analyzed by Mann-Whitney U test, and categorical data by Poisson distribution contingency tables or 
Fishers’ exact test. Correlations were analyzed by Spearman rank correlation coefficients. Factors 
that were significant associated with s-BAFF and BAFF-RQ after univariate analyses were then 
entered into multiple regression models (p<0.2 to enter, p>0.05 to stay) to determine the 
independence of potential correlations. Statistical analyses were performed with SPSS v17.0. 
 
Results 
BAFF promoter genotype and association with SLE 
In the currently studied Caucasian population the allele frequencies for the investigated SNPs in the 
BAFF gene promoter region were comparable with those reported in the HapMap database. 
Furthermore, the allele frequencies were similar for SLE patients and healthy controls (p>0.2) (Table 
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1). In addition, when comparing SLE patients and controls, no significant difference in genotype 
frequencies was found (p>0.1) (Table 1). As all but one individual expressed genotype AA for SNP 
rs3759465 (c.-514 A>G), this SNP was excluded from the haplotype analyses. The remaining four 
SNPs were in strong linkage disequilibrium (p<0.00001) and formed four common haplotypes 
(frequency >0.5%). No specific haplotype could be correlated with SLE and four common haplotype 
were found with similar frequencies in our studied SLE population and the normal controls (global 
haplotype association p-value=0.59) (Table 2).  
 
BAFF promoter variation and association with BAFF gene expression 
In SLE patients an increased BAFF mRNA levels was found compared to controls (RQ 1.8 ±0.63 
S.D. vs. 1.1 ±0.64 S.D. p<0.001). However, the increased BAFF-RQ was not associated with the 
presence of a particular investigated SNP. In addition, increased BAFF-RQ were not associated with 
a specific haplotype in our investigated SLE population (p-value=0.21). 
 
Serum-BAFF and association with BAFF promoter variation and BAFF gene expression 
The measured s-BAFF levels were nearly doubled in the SLE patients (1.73ng/μl.±1.10 S.D.) 
compared to controls (0.98ng/μl ±0.27 S.D. p<0.001) (Figure 2). Single allele-, genotype- and 
haplotype association analyses showed however no significant association with s-BAFF values in 
SLE patients (data not shown). In SLE patients, no correlation was found between s-BAFF and full-
length BAFF mRNA levels in PBMCs (R²; 0.007, p=0.4) (Figure 3). 
 
Clinical features and BAFF expression 
Demographics There was no association between increased s-BAFF levels and the patients age 
(p=0.9) or gender (p=0.2) in the SLE cohort compared with healthy controls. SLE patients that were 
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daily smokers (n=34) produced significantly increased s-BAFF than non-smokers patients, (2.23 
ng/μl ±1.10 S.D. vs. 1.83 ±1.10 S.D. p=0.025). 
Disease activity The investigated SLE population presented with a SLEDAI 2K scores of 6 (range 0-
39), while the patients VAS scores were 3 (range 0-9) and physician VAS scores were 2 (range 0-8).  
Physicians VAS scores correlated with s-BAFF levels (Rs 0.21, p=0.05). Single disease 
manifestations registered in SLEDAI and global activity scores (SLEDAI-2K, SDI) showed no 
significant correlation with s-BAFF or BAFF-RQ levels. The s-BAFF levels were not significantly 
different in patients with active renal (n=9; s-BAFF 1.86 ng/μl vs. 1.73, p=0.9), skin disease (n=21; 
s-BAFF 1.75 ng/μl vs. 1.73, p=0.9) or secondary Sjögren’s Syndrome (n= 33; s-BAFF 1.69 ng/μl vs. 
1.76, p= 0.6) compared to patients without these organ manifestation. Similarly, BAFF-RQ levels 
did not differ between patients with or without these organ involvements (data not shown, all p 
values>0.3). 
Autoantibodies  SLE patients with positive test of anti-dsDNA Ab (n=31) had increased levels of s-
BAFF compared with patients without anti-dsDNA Ab (2.2 ng/μl vs. 1.6, p=0.009), but similar 
findings of increased BAFF-RQ was not found in PBMCs (1.8 vs. 1.9, p>0.4) (data not shown). 
Increased s-BAFF and BAFF-RQ were rather not associated with the presence of anti-Sm, anti-SSA, 
anti-SSB or anti-RNP Ab (data not shown). In addition, neither correlations between anti-dsDNA 
Ab, ELISA (OD ratio 2.0, range 0-5.8) nor anti-dsDNA Ab, ELIA (2.3 IU/mL, range 0-450) and s-
BAFF levels or BAFF gene expression were found.  Other autoantibodies with quantitative levels 
like anti-Cardiolipin Ab and Rheumatoid factor showed neither correlation, (Table 3). 
Immune cells and other laboratory findings  In patients with SLE, several assays in serum were 
measured such as CRP (4 mg/L, range 1-21), haemoglobin (Hb) (13.2 g/dL, range 8,3-17) and IgA 
(2.4 g/L, range 0.4-9.2). We found that s-BAFF concentrations had a strong and independent positive 
correlation with CRP levels (: 0.40, p<0.001) and a negative correlation with Hb (: -0.32, 
p<0.001) and IgA levels (: -0.33, p=0.001) (Table 3). Furthermore, BAFF-RQ correlated inversely 
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with CD4+cells (: -0.27, p<0.012) and IgG levels (: -0.25, p=0.023), where median serum levels 
of CD4+cells were 0.55 x 109/L (range 0.1-1.6) and IgG 13.1 g/L, (range 5.0-27). Neither absolute 




In this cross sectional study we investigated several aspects of BAFF to increase our 
understanding of the regulation and contribution of BAFF in human SLE. We found that genetic 
variation in the promoter region of the BAFF gene was not associated with SLE susceptibility, BAFF 
gene expression or s-BAFF.  Furthermore, no linear correlation was observed between increased 
BAFF gene expression and increased s-BAFF levels. This observation together with the correlation 
found between s-BAFF levels and markers of the acute phase response suggest that s-BAFF 
production in SLE occurs mainly at local sites of inflammation. 
The role of polymorphisms of the BAFF encoding gene has been rarely investigated in human 
SLE, possibly because this gene seems to be highly conserved (19;27). However, there are data 
suggesting that the c.-871 C>T SNP in the 5’ promoter region of the BAFF gene increases disease 
susceptibility and circulating BAFF levels in patients with Sjögren’s syndrome (18;19). In our study, 
neither this SNP nor other single or combined variations in the 5’ promoter region of the BAFF gene, 
demonstrated disease association with SLE, which is in agreement with the only other study on this 
subject in a Japanese SLE cohort (17). The fact that BAFF gene polymorphisms were not reported 
with the main risk factors for SLE in genome wide association studies also indicates that BAFF 
polymorphisms have little impact on disease susceptibility (15;28-30).  
BAFF gene expression in PBMCs was increased in SLE patients, but this was not related to 
the presence of distinct disease manifestations. This is in accordance with the lack of association 
between BAFF expression and renal disease observed in lupus prone mice that strongly express anti-
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nucleosome and anti-dsDNA Ab (31). Up regulation of BAFF-mRNA has also been observed in the 
salivary glands of patients with primary Sjögren’s syndrome. However, we were unable to confirm 
such association in PBMCs of SLE patients. This discrepancy may be due to difference in used 
biological material (blood vs. salivary cells) where mRNA was isolated from or to the fact that 
secondary Sjögren’s syndrome developed from  SLE does not lead to germinal centre formation 
and/or BAFF expression in the salivary glands (6;32). We did find a strong inverse correlation of 
BAFF gene expression with numbers of CD4+T-cells and IgG levels, which both are considered to 
be immunological signs of disease activity in SLE (33;34). This is inconsistent with Morimoto and 
colleagues who suggested that autoantibody production is driven by BAFF produced by T-cells and 
may accordingly play a pathological role in SLE (35). However, their results are based on the 
expression of BAFF mRNA in isolated T-cells of SLE patients which was absent in T-cells from 
normal controls. Since neither s-BAFF levels nor their relation with BAFF gene expression in SLE 
patients were reported in that study, it is not possible to determine the extent to which the 
contribution of BAFF production by CD4+T-cells affects the s-BAFF levels. The significant 
discrepancy between the BAFF gene expression and s-BAFF levels reported here have also been 
reported elsewhere (12) and suggest that the origin of s-BAFF is more complex. Our data underscore 
the hypothesis that a negative regulatory feedback mechanisms may exist between s-BAFF levels 
and BAFF mRNA expression in PBMCs (19). This may also be the case in a specific transgenic 
mouse model where it was established that BAFF exerts an anti-inflammatory effect through B cell 
dependent up regulation of regulatory CD4+CD25+T-cells (36). 
In agreement with earlier reports, we found that almost two-thirds of studied SLE patients 
had increased s-BAFF levels (10;12;37). However, s-BAFF levels were neither associated with 
specific genotypes nor with mRNA expression levels in PBMCs and this could indicate that s-BAFF 
does not derive exclusively from circulating cells. The most striking findings in this study were 
prominent correlation between s-BAFF levels and features of the acute phase response (increased 
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CRP, lower albumen and Hb levels). Different inflammatory tissues have been shown to express 
BAFF locally (38-41), that accordingly also contributes to higher s-BAFF levels. Our data, in 
agreement with other studies, indicated that increased s-BAFF are closely related to systemic signs 
of inflammation and may not play a primary role in the autoimmune pathway of SLE (10;42).  
Given the diverse nature of SLE, we stratified patients by distinct clinical features, but were 
unable to detect whether patients with elevated s-BAFF were more likely to have active renal- or 
skin disease or secondary Sjögren’s syndrome. The only significant clinical correlation we found 
was that s-BAFF was increased in current smokers. These results support the observation that smoke 
inhalation may stimulate BAFF expression in epithelial airway cells (41;43;44) and emphasize the 
role for BAFF as a marker of inflammation. In contrast, we did not show an association between s-
BAFF levels and SLEDAI scores (Rs -0.2; p>0.8); which is in accordance with some but not all 
reports (10-12;20) and may partly reflect the rather crude nature of disease activity scoring systems 
(45). While we could not detect which particular type of organ inflammation was associated to the 
increased s-BAFF levels, the close correlation between s-BAFF and anti-dsDNA Ab suggested that 
there is a disease specific inflammatory process involving autoantibodies triggering the increased s-
BAFF levels.  
 There are several limitations to these results. The phenotype of SLE may vary in different 
populations, which implies that the findings in this Caucasian cohort can not be directly transferred 
to cohorts of different ethnicity. While our results do not demonstrate an influence of polymorphisms 
on gene expression nor on s-BAFF levels, such a role for these polymorphisms cannot be wholly 
excluded because of sample sizes and the possibility of a type II error. Therefore, further studies that 
include more patients and controls are required before a final conclusion can be made. Similar 
restrictions apply to our subgroup analyses, especially for patients with active renal disease. Finally, 
SLE is a chronic disease with intermittent disease activity and our cross sectional study design does 
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not allow any conclusions about variations of BAFF expression levels over time, although s-BAFF 
level variation seem to be limited (10;12).  
In conclusion, polymorphisms in the regulatory region of the BAFF gene do in all probability 
neither contribute to the increased BAFF gene expression or increased s-BAFF levels nor to the 
susceptibility to SLE in Caucasian patients. There is no linear correlation between increased BAFF 
gene expression measured in PBMCs and increased s-BAFF levels. As s-BAFF levels are strongly 
correlated with markers of inflammation, most of the produced s-BAFF may originate from local 
inflamed tissues.  
 
Key messages: 
1. Serum-BAFF levels correlate strongly with acute phase reactants. 
2. There is no linear correlation between BAFF gene expression in PBMCs and serum-BAFF levels. 
3. BAFF gene promoter polymorphisms do not contribute to SLE disease susceptibility. 
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Table 1  Allele- and genotype frequency in SLE patients and controls in a Caucasian population.   










n=110    
SNP Allele % % % Genotypes n (%) n (%) p-value
          
Rs9514827 T 61 63 70 TT 37 (37) 43 (39)  
 C 39 37 30 CT 49 (49) 53 (48) 0.89 
     CC 15 (15) 14 (13)  
          
Rs3759467* T 83 85 81 TT 69 (69) 80 (73)  
 C 17 15 19 CT 30 (30) 27 (25) 0.68 
     CC 2 (2) 3 (3)  
Rs1041569*  A 85 79 77 AA 76 (75) 70 (64)  
 T 15 21 23 AT 19 (19) 34 (31) 0.13 
     TT 6 (6) 6 (6)  
          
Rs9514828 T 51 56 47 TT 24 (24) 33 (30)  
 C 49 44 53 CT 55 (55) 56 (51) 0.59 
     CC 22 (22) 21 (19)  
          
Rs3759465 A 99 100 96 AA 100 (99) 
110 
(100) 0.97 






Table 2  Haplotype frequencies for BAFF promoter region in SLE patients and controls. 
       
   SLE Controls OR  
 Haplotypeª Total n=101 n=110 (95% CI) p-value 
              
(1) CTAT 0.37 0.38 0.36 1  
(2) TTAC 0.28 0.29 0.27 1.02 (0.62 - 1.69) 0.93 
(3) TTTT 0.16 0.12 0.19 0.65 (0.37 - 1.14) 0.14 
(4) TCAC 0.16 0.17 0.15 1.10 (0.62 - 1.97) 0.74 
 rare pool 0.03 0.04 0.02 1.37 (0.36 - 5.18) 0.64 
       
Global haplotype association p-value: 0.59 
ªHaplotype order rs9514827 (c.-2841 T>C), rs3759467 (c.-2704 T>C), rs1041569  




























Table 3 Linear regression analysis (95% CI.) of BAFF-RQ or s-BAFF and laboratory findings in SLE (n=101). 
   BAFF-RQ s-BAFF 
 Univariate  Multivariate  Univariate  Multivariate  
Feature β p-value β p-value β p-value  β p-value 
Anti-dsDNA ELISA -0.16 0.57   0.10 0.66   
Anti-dsDNA ELIA -0.30 0.18   -0.21 0.28   
aCL IgG, U/mL 0.36 0.10   0.00 0.99   
aCL IgM, U/mL -0.45 0.08 -0.130 0.390 -0.28 0.22   
RF, IU/mL 0.24 0.19   0.21 0.20   
C3, g/L 0.19 0.33   0.19 0.26   
C4, g/L 0.08 0.69   0.01 0.98   
ESR, mm/hour -0.31 0.25   -0.29 0.22   
CRP, mg/L 0.29 0.15   0.53 <0.001 0.398 <0.001 
Hb, g/dL -0.19 0.48   -0.37 0.10 -0.324 <0.001 
Leukocyte,109/L 0.02 0.90   -0.26 0.10 -0.118 0.274 
Tot. Lymph., 109/L  -0.19 0.41   0.04 0.85   
      B-cells, 109/L 0.22 0.25   -0.08 0.63   
      NK-cells, 109/L -0.08 0.72   0.26 0.15 0.181 0.117 
CD4+ cells, 109/L -0.53 0.01 -0.271 0.012 -0.07 0.73   
CD8+ cells, 109/L 0.39 0.09   -0.05 0.81   
IgA, g/L -0.23 0.22   -0.33 0.04 -0.333 0.001 
IgM, g/L 0.52 0.04 0.142 0.365 0.10 0.67   
IgG, g/L -0.45 0.03 -0.254 0.023 -0.04 0.83   
Albumen, g/L -0.59 0.02 -0.149 0.169 -0.22 0.34   
anti-dsDNA; ELISA (OD ratio), ELIA (IU/mL), RF; Rheumatoid Factor. β; Standardized coefficients.   
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Supplemental Table  Primers and probes used in this study. Bold capital letters; Examined SNPs 
Primers and probes, name Sequence (5' -3') Fluorescence  label 
Primers and probes used for SNPs analysis  
forward primer: rs9514827, rs3759467, rs1041569 gaggggaacgactcac  
reverse primer: rs9514827, rs3759467, rs1041569 ttatcctggcccccaa  
anchor, c.-2841 agagaaattgctttctagcactgcgt 3' fluorescein 
sensor, c.-2841 catcctttcatttcCgcatgtat 5' LC red 705 
anchor, c.-2704,c.-2701 atggcaaggttactccgtatg 3' fluorescein 
sensor, c.-2704,c.-2701 tcaccctaaTtgTtctggaac 5' LC red 640 
forward primer: rs9514828 caacatgggagttgtagac  
reverse primer: rs9514828 ccttctgggactcatcac  
anchor, c.-871 aggcaaggctgattctcctca 3' fluorescein 
sensor, c.-871 tagtatcatattgagCggggact 5' LC red 640 
forward primer: rs3759465 ccctccgattggattgc  
reverse primer: rs3759465 actgttaataaatcactctctagc  
anchor, c.-514 ttatttttatgacagcagcaggaactt 3' fluorescein 
sensor, c.-514 agctCatctgaccttcacatt 5' LC red 705 
Primers and probes used for BAFF gene expression analysis, RT-PCR 
Probe 2*, BAFF caggagaa 5'TAMRA 
BAFF forward primer actgaaaatctttgaaccaccag  
BAFF reverse primer ttgcaagcagtcttgagtgac  
Probe 42*, β2M catccage 3'FAM 
β2M forward primer ttctggcctggaggctatc  
β2M reverse primer tcaggaaatttgactttccattc  




Figure 1.  SNPs in the 5’ regulatory region of the BAFF gene used in the study.   
rs9514827 (c.-2841 T>C), rs3759467 (c.-2704 T>C), rs1041569 (c.-2701 A>T), rs9514828 (c.-871 
C>T) and rs3759465 (c.-514   A>G), (www.hapmap.org and www.ncbi.nlm.nih.gov/snp) 
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Figure 2. Serum BAFF levels in SLE patients compared with healthy controls. The results are shown 
in box plots. The line inside the boxes indicates the medians; the outer borders of the boxes indicate 

















Figure 3.  Low concordance between BAFF mRNA gene expression and serum BAFF in SLE 







R² Linear = 0.007
 
